- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
FDA Puts New Limits on Oral MS Drug
Reacting to a death associated with the multiple sclerosis drug fingolimod (Gilenya), the FDA said patients with certain cardiac risk factors should not take the oral agent.
The death was reported last year and the agency had promised to investigate it.
In an announcement on Monday, the FDA said it still didn't know whether fingolimod caused the patient's death, but nevertheless it was adding new contraindications to the drug's label, as well as a beefed-up recommendation for monitoring patients after dosing.
Read the full story: http://hcp.lv/Md4ptW
Source: MedPage Today
Dr Kathy Zackowski Discusses the Importance of Rehabilitation Research and Trials in MS
April 26th 2024Kathy Zackowski, PhD, National MS Society, expresses the inherent value of quality rehabilitation trials for broadening clinical understandings of multiple sclerosis (MS) and bettering patient outcomes.
Read More
Distinguishing Biomarkers Identified in MS Outcomes
March 19th 2024Results from this cohort study found that levels of glial fibrillary acid protein, cerebral spinal fluid, and neurofilament heavy chain are distinguishable biomarkers that are associated with disease outcomes in multiple sclerosis (MS).
Read More
